Bristol-Myers Squibb Company (BMY) Reaches New 12-Month High at $63.65

Bristol-Myers Squibb Company (NYSE:BMY) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $63.65 and last traded at $63.63, with a volume of 1,985,947 shares trading hands. The stock had previously closed at $62.93.

A number of research analysts have commented on the stock. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $65.00 price target (up from $62.00) on shares of Bristol-Myers Squibb in a research report on Thursday, September 7th. Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $64.20 price target on the stock. in a research report on Thursday, September 7th. Credit Suisse Group reiterated a “hold” rating on shares of Bristol-Myers Squibb in a research report on Friday, September 8th. Jefferies Group LLC increased their price target on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the company a “buy” rating in a research report on Monday, September 11th. Finally, Hilliard Lyons cut shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price target on the stock. in a research report on Tuesday, September 12th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. Bristol-Myers Squibb has an average rating of “Hold” and an average price target of $62.66.

The company has a market cap of $103.95 billion, a price-to-earnings ratio of 23.150 and a beta of 1.18. The firm’s 50 day moving average is $58.94 and its 200-day moving average is $56.02.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. Bristol-Myers Squibb’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.69 EPS. On average, equities analysts expect that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 2.48%. The ex-dividend date is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 56.73%.

In other news, Director Theodore R. Samuels II purchased 6,000 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were acquired at an average price of $55.94 per share, with a total value of $335,640.00. Following the transaction, the director now owns 18,000 shares of the company’s stock, valued at $1,006,920. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of BMY. Nisa Investment Advisors LLC grew its position in shares of Bristol-Myers Squibb by 1.8% during the 1st quarter. Nisa Investment Advisors LLC now owns 610,253 shares of the biopharmaceutical company’s stock worth $33,186,000 after buying an additional 10,541 shares in the last quarter. Quantitative Systematic Strategies LLC lifted its stake in shares of Bristol-Myers Squibb by 447.5% during the 1st quarter. Quantitative Systematic Strategies LLC now owns 32,128 shares of the biopharmaceutical company’s stock worth $1,747,000 after purchasing an additional 26,260 shares during the last quarter. Hartford Financial Management Inc. lifted its stake in shares of Bristol-Myers Squibb by 1.8% during the 1st quarter. Hartford Financial Management Inc. now owns 69,247 shares of the biopharmaceutical company’s stock worth $3,765,000 after purchasing an additional 1,223 shares during the last quarter. Ledyard National Bank lifted its stake in shares of Bristol-Myers Squibb by 25.5% during the 1st quarter. Ledyard National Bank now owns 27,248 shares of the biopharmaceutical company’s stock worth $1,482,000 after purchasing an additional 5,533 shares during the last quarter. Finally, Bollard Group LLC lifted its stake in shares of Bristol-Myers Squibb by 7.8% during the 1st quarter. Bollard Group LLC now owns 186,473 shares of the biopharmaceutical company’s stock worth $10,140,000 after purchasing an additional 13,425 shares during the last quarter. 68.88% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Bristol-Myers Squibb Company (BMY) Reaches New 12-Month High at $63.65” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/09/20/bristol-myers-squibb-company-bmy-reaches-new-12-month-high-at-63-65.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply